| I-007 Mahmoud Ali mastering upset plots: a comprehensive tutorial for effective data visualization in pharmacometrics and drug development Wednesday 10:20-11:50 |
| I-008 Nikolaos Alimpertis Leveraging the Finite Absorption Time (F.A.T.) Concept for Advancing PBPK Modeling and Pharmacometric structural models: Moving MIDD to Model Informed Drug Development and Assessment (MIDDA) Wednesday 10:20-11:50 |
| I-012 Innocent Asiimwe The Applied Pharmacometrics Training Program – Year 3 Sustainability Wednesday 10:20-11:50 |
| I-014 Sally Babiker Dose rationale for bedaquiline in paediatric patients with multi drug-resistant tuberculosis Wednesday 10:20-11:50 |
| I-017 Pavel Balazki User-friendly and Quality-Controlled PBPK/QSP M&S Framework in R for Regulatory Submissions using Open Systems Pharmacology Software Wednesday 10:20-11:50 |
| I-079 Giuseppe De Nicolao A mixed effect multi-funnel model for country surveillance of antibiotic resistance: evidence from the WHO GLASS dashboard Wednesday 10:20-11:50 |
| I-088 Giovanni Di Veroli Bridging the gap between secondary pharmacology and hemodynamics findings via Quantitative Systems modelling Wednesday 10:20-11:50 |
| I-101 Alan Faraj Model-based approaches to prospectively power pediatric pharmacokinetic trials with limited sample size Wednesday 10:20-11:50 |
| I-110 Sophie Fischer-Holzhausen Development of a gestational Physiologically Based Kinetic model to predict rat dam and fetus exposure in PK-Sim/MoBi Wednesday 10:20-11:50 |
| I-112 Thomas Frank Automating pharmacometrics reporting using R Markdown Wednesday 10:20-11:50 |
| II-033 Niels Hendrickx Evaluation of treatment effects in genetic ataxias using SARA score modelling: comparison of multiple trial designs by a large trial simulation framework Wednesday 15:20-16:50 |
| II-037 Sara Carolina Henriques Unveiling the Potential of Cmax ƒ2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies Wednesday 15:20-16:50 |
| II-043 Andrew Hooker Generating uncertainty estimates in empirical forest plots Wednesday 15:20-16:50 |
| II-045 Ziheng Hu Choice of Exposure Metric in Exposure-Response Modeling Wednesday 15:20-16:50 |
| II-051 Ibrahim Ince Qualification of the Open Systems Pharmacology PBPK modeling Platform for simulation of transporter Drug-Drug-Interactions Wednesday 15:20-16:50 |
| II-068 Daniel Kaschek Using the M3 Method in Exploratory Plots and in NCA Wednesday 15:20-16:50 |
| II-069 Csaba Katai An asymptotic description of a basic FcRn-regulated clearance mechanism and its implications for PBPK modelling of large antibodies Wednesday 15:20-16:50 |
| II-097 Valentin Legras Sunburst Plots for Analyzing the Impact of Drugs on CRS Wednesday 15:20-16:50 |
| III-011 John Maringwa Assessing Approaches for Handling Missing Precision Measures Issue in Model-Based Meta Analysis (MBMA) Thursday 09:50-11:20 |
| III-029 Zeyar Mohammed Ali Evaluation of extrapolation potential of IMPRES-M, a non-parametric Impulse-Response Modeling framework when applied to pharmacokinetic profiles of different dosing frequencies Thursday 09:50-11:20 |
| III-065 Mariana Pereira Etravirine's Pharmacokinetics Explored: PBPK Modeling and DDI Analysis with Efavirenz for Cancer Treatment Thursday 09:50-11:20 |
| III-074 Cesar Pichardo The International Society of Pharmacometrics’ Special Interest Group on Quantitative Systems Pharmacology (ISoP QSP SIG): Recent Developments and Future Vision Thursday 09:50-11:20 |
| III-083 Anne Ravix Numerical validation of Tucuxi, a promising new Bayesian adaptation tool Thursday 09:50-11:20 |
| III-093 Matthew Riggs bbr.bayes: An Open-Source Tool to Facilitate an Efficient, Reproducible Bayesian Workflow Using NONMEM Thursday 09:50-11:20 |
| III-108 Andrew Santulli nonmem2mrgsolve: An R package for Automated NONMEM to mrgsolve Translation Thursday 09:50-11:20 |
| IV-010 Erik Sjögren Absorption, Bioavailability, and Immunogenicity after Subcutaneous Administration: Evaluation of a Subcutaneous Platform within the Open Systems Pharmacology framework Thursday 15:00-16:30 |
| IV-034 Florencia Tettamanti Predicting Progression Free Survival from Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL) Thursday 15:00-16:30 |
| IV-065 Peter Velickovic Translational pharmacology and dose rationale for imatinib and doramapimod as a host-directed therapy for the treatment of pulmonary tuberculosis Thursday 15:00-16:30 |
| IV-069 Laura Villain Considerations for the application of PBPK to optimize drug therapies in special populations: The Open Systems Pharmacology solutions Thursday 15:00-16:30 |
| IV-087 Mélanie Wilbaux How to handle population pharmacokinetics modeling in the context of a regulatory submission for a compound already well-characterized in other settings? A case-study with nivolumab in urothelial cancer. Thursday 15:00-16:30 |
| IV-089 Insa Winzenborg Uncovering Bias in Exposure-Response Relationships: Investigating the Impact of Exposure Calculation for Irregular Dosing Regimens Thursday 15:00-16:30 |
| IV-090 Daniel Wojtyniak Influential factors on the type I error rate in pharmacometrics models using individual model averaging or standard approach Thursday 15:00-16:30 |
| IV-099 Koichiro Yoneyama Impact of Imbalanced Baseline Responses among Dose Levels in the Exposure-Response Analysis by Nonlinear Mixed-Effect Modeling Thursday 15:00-16:30 |
| IV-114 Jochen Zisowsky Target-mediated drug disposition of monoclonal antibody binding to plasma soluble target: some insights from PBPK/PD and popPK/PD approaches Thursday 15:00-16:30 |
